Piramal Pharma Limited

NSEI:PPLPHARMA Stock Report

Market Cap: ₹300.0b

Piramal Pharma Future Growth

Future criteria checks 4/6

Piramal Pharma is forecast to grow earnings and revenue by 73.5% and 12.2% per annum respectively. EPS is expected to grow by 74.4% per annum. Return on equity is forecast to be 7.6% in 3 years.

Key information

73.5%

Earnings growth rate

74.4%

EPS growth rate

Pharmaceuticals earnings growth18.1%
Revenue growth rate12.2%
Future return on equity7.6%
Analyst coverage

Good

Last updated13 Aug 2024

Recent future growth updates

Earnings Update: Here's Why Analysts Just Lifted Their Piramal Pharma Limited (NSE:PPLPHARMA) Price Target To ₹161

Feb 02
Earnings Update: Here's Why Analysts Just Lifted Their Piramal Pharma Limited (NSE:PPLPHARMA) Price Target To ₹161

Recent updates

Here's Why Piramal Pharma (NSE:PPLPHARMA) Has A Meaningful Debt Burden

Jul 14
Here's Why Piramal Pharma (NSE:PPLPHARMA) Has A Meaningful Debt Burden

Estimating The Intrinsic Value Of Piramal Pharma Limited (NSE:PPLPHARMA)

Jun 17
Estimating The Intrinsic Value Of Piramal Pharma Limited (NSE:PPLPHARMA)

We Think That There Are Issues Underlying Piramal Pharma's (NSE:PPLPHARMA) Earnings

May 21
We Think That There Are Issues Underlying Piramal Pharma's (NSE:PPLPHARMA) Earnings

It's A Story Of Risk Vs Reward With Piramal Pharma Limited (NSE:PPLPHARMA)

Mar 26
It's A Story Of Risk Vs Reward With Piramal Pharma Limited (NSE:PPLPHARMA)

Estimating The Fair Value Of Piramal Pharma Limited (NSE:PPLPHARMA)

Feb 28
Estimating The Fair Value Of Piramal Pharma Limited (NSE:PPLPHARMA)

Earnings Update: Here's Why Analysts Just Lifted Their Piramal Pharma Limited (NSE:PPLPHARMA) Price Target To ₹161

Feb 02
Earnings Update: Here's Why Analysts Just Lifted Their Piramal Pharma Limited (NSE:PPLPHARMA) Price Target To ₹161

Calculating The Intrinsic Value Of Piramal Pharma Limited (NSE:PPLPHARMA)

Nov 09
Calculating The Intrinsic Value Of Piramal Pharma Limited (NSE:PPLPHARMA)

Calculating The Fair Value Of Piramal Pharma Limited (NSE:PPLPHARMA)

Aug 11
Calculating The Fair Value Of Piramal Pharma Limited (NSE:PPLPHARMA)

Earnings and Revenue Growth Forecasts

NSEI:PPLPHARMA - Analysts future estimates and past financials data (INR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/2027117,0819,157N/AN/A2
3/31/2026104,8415,5188,034N/A6
3/31/202592,3732,2573,572N/A6
6/30/202483,735278N/AN/AN/A
3/31/202481,7121782,92510,045N/A
12/31/202378,435-333N/AN/AN/A
9/30/202376,009-1,336-9928,655N/A
6/30/202374,096-1,760N/AN/AN/A
3/31/202370,816-1,865-4,8094,839N/A
12/31/202272,228-325-6,6343,382N/A
9/30/202269,5352,210N/AN/AN/A
6/30/202267,5322,626N/AN/AN/A
3/31/202267,3413,760-1,2317,664N/A
3/31/202158,8687,708-435,516N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PPLPHARMA's forecast earnings growth (73.5% per year) is above the savings rate (6.7%).

Earnings vs Market: PPLPHARMA's earnings (73.5% per year) are forecast to grow faster than the Indian market (17% per year).

High Growth Earnings: PPLPHARMA's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: PPLPHARMA's revenue (12.2% per year) is forecast to grow faster than the Indian market (10.1% per year).

High Growth Revenue: PPLPHARMA's revenue (12.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PPLPHARMA's Return on Equity is forecast to be low in 3 years time (7.6%).


Discover growth companies